This episode of The Motley Fool's Market Checkup features a 20% biotech pop, big changes coming to two big pharma stocks, and the Affordable Care Act's October 1 insurance exchange debut.
In this video, health-care analysts David Williamson and Max Macaluso discuss the Reuters report that Johnson & Johnson is attracting interest from private equity. J&J is looking to unload the diagnostics portion of its medical devices and diagnostics business and such companies as Blackstone, KKR, and the Carlyle Group have supposedly offered sums approaching $5 billion. The diagnostics business is slower growing, has older devices, and has generally worse margins than the health-care conglomerate's other segments.
David and Max take a closer look at the news surrounding the J&J's diagnostics unit, whether J&J is making the right decision to change its corporate structure, and puts today's news in perspective amidst the big changes happening in the big pharma industry.
